PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 137 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,483,775 | +435.3% | 1,108,140 | +250.1% | 0.05% | +350.0% |
| Q4 2022 | $3,453,015 | -83.9% | 316,500 | -87.5% | 0.01% | -85.9% |
| Q3 2022 | $21,395,000 | -35.5% | 2,537,993 | -39.4% | 0.08% | -39.3% |
| Q2 2022 | $33,153,000 | -52.0% | 4,191,200 | +43.8% | 0.14% | -48.9% |
| Q1 2022 | $69,030,000 | -16.6% | 2,915,100 | +20.5% | 0.27% | -17.0% |
| Q4 2021 | $82,756,000 | +6.4% | 2,419,763 | -44.8% | 0.33% | -3.2% |
| Q3 2021 | $77,743,000 | +50.0% | 4,387,300 | +279.8% | 0.34% | +46.4% |
| Q2 2021 | $51,845,000 | +112.4% | 1,155,200 | +22.6% | 0.23% | +104.4% |
| Q1 2021 | $24,406,000 | +120.1% | 942,300 | +71.3% | 0.11% | +111.1% |
| Q4 2020 | $11,088,000 | +468.0% | 550,000 | +238.5% | 0.05% | +350.0% |
| Q3 2019 | $1,952,000 | -21.8% | 162,500 | +35.4% | 0.01% | +9.1% |
| Q4 2017 | $2,496,000 | – | 120,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $56,331,209 | 18.32% |
| Kynam Capital Management, LP | 1,375,000 | $31,625,000 | 4.08% |
| BVF INC/IL | 3,775,900 | $86,845,700 | 3.18% |
| Cormorant Asset Management, LP | 1,700,000 | $39,100 | 2.58% |
| RTW INVESTMENTS, LP | 4,600,799 | $105,818,377 | 2.20% |
| Ghost Tree Capital, LLC | 225,000 | $5,175,000 | 1.53% |
| 683 Capital Management, LLC | 791,000 | $18,193,000 | 1.36% |
| Ikarian Capital, LLC | 211,400 | $4,862,200 | 1.10% |
| Ikarian Capital, LLC | 211,400 | $4,862,200 | 1.10% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 105,486 | $2,426,178 | 1.00% |